Accueil・Liste d'Actions・Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc

Ouvert

SecteurSoins de santé

2.54 7.17

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.2800000000000002

Max

2.48

Chiffres clés
By Trading Economics
Revenu	171M 123M
BPA	-0.15
Employés	202
EBITDA	179M 134M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+298.32% upside

Dividendes
By Acuity
Prochains Résultats	11 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-126M 271M
Ouverture précédente	-4.63
Clôture précédente	2.54

Rocket Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 nov. 2026, 21:04 UTC

Correlated Moves

Rocket Pharmaceuticals, Inc. shares fell sharply, reflecting a broader decline in the biotechnology sector, as the SPDR S&P Biotech ETF (XBI) also dropped significantly.

4 nov. 2026, 21:52 UTC

Rocket Pharmaceuticals, Inc. saw a significant increase in after-market trading, continuing its upward trend after four consecutive sessions of gains.

3 nov. 2026, 21:02 UTC

Rocket Pharmaceuticals, Inc. is trading higher on Tuesday, despite an intraday pullback, remaining above its 20-day moving average and near the upper end of its one-month range.

2 nov. 2026, 22:02 UTC

Rocket Pharmaceuticals, Inc. is experiencing a significant decline in after-market trading, continuing a trend of lower returns over the last three sessions.

30 oct. 2026, 19:53 UTC

Rocket Pharmaceuticals, Inc. shares fell sharply after pulling back from an early session high, remaining above its 20-day moving average.

29 oct. 2026, 20:07 UTC

Rocket Pharmaceuticals, Inc. shares declined, pulling back from an earlier peak.

28 oct. 2026, 22:21 UTC

Rocket Pharmaceuticals, Inc. shares are lower in after-market trading, reversing earlier gains to reach their lowest point of the day.

27 oct. 2026, 20:01 UTC

Rocket Pharmaceuticals, Inc. shares are up sharply, showing strong momentum with a peak return exceeding 10% since Monday's close.

26 oct. 2026, 20:07 UTC

Rocket Pharmaceuticals Inc shares are declining, having reached a session low earlier before recovering slightly, but remain below the 20-day moving average.

23 oct. 2026, 20:07 UTC

Rocket Pharmaceuticals Inc shares are declining amid a broadly lower market, influenced by mixed economic indicators and rising oil prices raising inflation concerns.

22 oct. 2026, 20:07 UTC

Rocket Pharmaceuticals Inc shares are trading sharply higher, rebounding from a recent decline, as the broader market experiences significant upward movement.

21 oct. 2026, 22:21 UTC

Rocket Pharmaceuticals Inc. advanced sharply in after-market trading, closing at its peak.

20 oct. 2026, 20:21 UTC

Rocket Pharmaceuticals Inc gained sharply in after-market trading, rising since Tuesday's close.

19 oct. 2026, 20:07 UTC

Correlated Moves

Rocket Pharmaceuticals shares are higher, supported by positive clinical trial results in the biotech sector, alongside gains in the SPDR S&P Biotech ETF.

16 oct. 2026, 21:01 UTC

Rocket Pharmaceuticals Inc shares advanced in after-market hours on Friday.

15 oct. 2026, 20:02 UTC

Rocket Pharmaceuticals Inc is trading sharply higher, reversing a recent trend of declines after closing lower in each of the previous four sessions.

13 oct. 2026, 20:01 UTC

Rocket Pharmaceuticals Inc shares fell sharply, continuing a downward trend amid broader market weakness, remaining well below their 20-day moving average.

12 oct. 2026, 20:06 UTC

Rocket Pharmaceuticals Inc shares are declining, continuing a downward trend since Friday, finishing near session lows and significantly below its 20-day moving average.

9 oct. 2026, 21:10 UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, showing a notable increase since Friday's close while remaining near the lower end of its one-month range.

8 oct. 2026, 23:10 UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, moving up since Thursday's close despite pulling back from an earlier peak.

7 oct. 2026, 20:07 UTC

Social Media

News

Rocket Pharmaceuticals' gene therapy candidate RP-A501 shows promising initial results; shares are higher since Tuesday, despite earlier intraday weakness.

6 oct. 2026, 22:01 UTC

News

Rocket Pharmaceuticals secures a $150 million credit facility with Hercules Capital to bolster its financial position and support its Phase 2 study of RP-A501.

5 oct. 2026, 20:06 UTC

Rocket Pharmaceuticals Inc is advancing amid a broader market recovery, despite experiencing a significant decline over the past month and remaining near its recent lows.

2 oct. 2026, 19:45 UTC

Rocket Pharmaceuticals Inc shares fell sharply, continuing a downward trend since Thursday and remaining significantly below its 20-day moving average.

1 oct. 2026, 21:01 UTC

Rocket Pharmaceuticals Inc advanced in after-market trading on Thursday, recovering sharply from earlier losses amid broader market challenges.

30 sept. 2026, 20:07 UTC

Rocket Pharmaceuticals Inc is gaining in today's trading session, advancing since Tuesday's close, despite a pullback from earlier session highs.

29 sept. 2026, 23:01 UTC

Rocket Pharmaceuticals Inc is trading modestly higher in after-market hours following Tuesday's close, despite a significant decline over the past month.

28 sept. 2026, 23:26 UTC

Rocket Pharmaceuticals Inc gained in after-market hours on Monday, recovering from earlier losses, though it remains significantly lower compared to last month's close.

25 sept. 2026, 23:56 UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, gaining significantly since Friday's close after a recent decline over the past month.

24 sept. 2026, 20:01 UTC

Rocket Pharmaceuticals Inc shares fell sharply, reaching their lowest point of the day and remaining well below the 20-day moving average.

Comparaison

Variation de prix

Rocket Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

298.32% hausse

Prévisions sur 12 Mois

Moyen 9.5 USD 298.32%

Haut 15 USD

Bas 4 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

Achat

Maintien

Vente

Basé sur 11 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.